The Abramson Cancer Center (ACC) has a well-established internal, Institutional, and external Planning and Evaluation (P&E) process that engages leaders, members, and advisors from multiple disciplines, perspectives and levels. The goal of this process is to guide future directions, set priorities and prioritize investments of the Center while, at the same time, providing ongoing mechanisms to monitor, assess and adjust research progress, Programs, Shared Resources, allocations, and strategies. This cohesive process is supported by highly integrated and effective bodies, such as the Senior Leaders, Executive Committee, Program Leaders, Shared Resource Advisory Committees, and the External Scientific Advisory Board (ESAB), which provides critical advice and feedback from experts. The Planning and Evaluation process has resulted in changes in Program focus, development of new Cores, changes in clinical research operations, and prioritization of Developmental Funds. Complementing these efforts are Programmatic, Divisional and Center-wide research seminars, meetings and retreats that foster new interactions and collaborations with Penn colleagues and external experts. Strategic planning is embedded in the ACC and Penn culture. The ACC plan of 2008-2013 set forth the goals for this period, including accelerating the translation of basic science discoveries into investigator-initiated clinical trials, establishing a comprehensive molecular profiling and personalized medicine initiative, enhancing behavioral interventions to reduce cancer risk, and promoting translation of ACC research. Soon after his appointment, the Center Director, Dr. Dang, defined his vision through 2020, and charged a group to recommend strategies to realize the Center's goals in translational research and precision medicine. A defining accomplishment has been $20M from the Institution to establish innovative transdisciplinary programmatic efforts in translational cancer research, which are fueled by multi-year Institutional grants and resources in high priority areas. Rigorous internal review of Programs, Shared Resources, Developmental Funds, and strategic plan reviews by the ESAB ensure that the ACC continues to strive for excellence and adheres to NCI guidelines. The ACC responds to all ESAB recommendations and then reports on its actions. Taken together, the integrated P&E processes have successfully guided the growth and development of the ACC during the project period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-44
Application #
9836821
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Jang, Jeong Hoon; Manatunga, Amita K; Taylor, Andrew T et al. (2018) Overall indices for assessing agreement among multiple raters. Stat Med 37:4200-4215
Scheel, John R; Kim, Eunhee; Partridge, Savannah C et al. (2018) MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol 210:1376-1385
Romero, Sally A D; Brown, Justin C; Bauml, Joshua M et al. (2018) Barriers to physical activity: a study of academic and community cancer survivors with pain. J Cancer Surviv 12:744-752
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7
Raghunathan, Nirupa Jaya; Korenstein, Deborah; Li, Qing S et al. (2018) Determinants of mobile technology use and smartphone application interest in cancer patients. Cancer Med 7:5812-5819
Hordeaux, Juliette; Wang, Qiang; Katz, Nathan et al. (2018) The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. Mol Ther 26:664-668
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10:
Torre, Eduardo; Dueck, Hannah; Shaffer, Sydney et al. (2018) Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH. Cell Syst 6:171-179.e5

Showing the most recent 10 out of 1047 publications